Skip to main content
. 2018 Dec 24;21(8):1726–1734. doi: 10.1038/s41436-018-0409-6

Table 3.

Facilitators and barriers to participation in future somatic gene editing clinical trials

Facilitators Patients N= 32 (%)a Parents N= 31 (%)a Physicians N= 17 (%)a
I want to help other patients with SCD 31 (97) 27 (87) 13 (76)
I want to contribute to science 15 (47) 22 (71) 11 (65)
It would be better to do something rather than just wait for [my/my child’s/my patient’s] SCD to get worse 26 (81) 24 (77) 11 (65)
I hope it would help [my/my child’s/my patient’s] SCD 27 (84) 27 (87) 15 (88)
I expect that it would help[my/my child’s/my patient’s] SCD 22 (69) 26 (84) 15 (88)
Maybe it would help [my/my child’s/my patient’s] SCD in the long run, if the research succeeds 21 (66) 29 (94) 14 (82)
For the sake of my loved ones 24 (75) 21 (68) n/a
Barriers
 It seems too dangerous 20 (63) 18 (58) 8 (47)
 It seems like a lot of work for [me/my child/my patient] to be involved in the study 12 (38) 10 (32) 6 (35)
 I don’t want [me/my child/my patient] to be a guinea pig 11 (34) 17 (55) 2 (12)
 I don’t like the idea of messing with [my/my child’s/my patient’s] genes 18 (56) 21 (68) 4 (24)
 The purpose of the study would not solely benefit [me/my child/my patient] directly 2 (6) 9 (29) 5 (29)

aResponses included 0 = Not a Reason, 1 = Minor Reason, 2 = Moderate Reason, 3 = Strong Reason. Scores of 2 and 3 were used to calculate the numbers/percentages above.